Treatment News : FDA Rejects Elvitegravir and Cobicistat as Individual Meds

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » April 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


April 30, 2013

FDA Rejects Elvitegravir and Cobicistat as Individual Meds

The U.S. Food and Drug Administration has rejected Gilead Sciences’ application for approval of the HIV antiretrovirals elvitegravir and cobicistat for use as stand-alone drugs, but the reason was because of “deficiencies in documentation and validation of certain quality testing procedures and methods,” the company stated in a release. Gilead submitted new drug applications to the FDA for the drugs in June 2012. The FDA did not raise safety concerns about either drug.

Both cobicistat, which, like ritonavir, boosts the levels of other HIV medications, and the integrase inhibitor elvitegravir are already components of Gilead’s once-daily, single-pill combination therapy Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir), which the FDA approved in August of last year.

Elvitegravir needs to be taken once a day, boosted by cobicistat, and operates similarly to Isentress (raltegravir), which is dosed at twice a day.

The company stressed it is working with the FDA to address the agency’s questions.

To read a Reuters story about the FDA rejection, click here.

To read the Gilead release, click here.

Search: U.S. Food and Drug Administration, FDA, Gilead Sciences, elvitegravir, cobicistat, Stribild, emtricitabine, tenofovir, Isentress, raltegravir

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.